Vimarsana
Biggest News Aggregation in the World

Metrics Plus News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Metrics Plus. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Metrics Plus Today - Breaking & Trending Today

ATS 2024 Data Support Triple Therapy FF/UMEC/VI as Preferred Option for COPD - Vimarsana News

ATS 2024 Data Support Triple Therapy FF/UMEC/VI as Preferred Option for COPD

New data reveal that starting furoate/umeclidinium/vilanterol (FF/UMEC/VI) without delay not only significantly reduces exacerbations and health care costs but also enhances adherence and persistence for patients with chronic obstructive pulmonary disease (COPD) compared with other therapies.

Source: ajmc.com
Real-World Users of Triple Therapy for Asthma in the US - Vimarsana News

Real-World Users of Triple Therapy for Asthma in the US

This retrospective cohort study evaluated baseline demographics, clinical characteristics, and treatment patterns of US patients with asthma who newly initiated single- or multiple-inhaler triple therapy.

Source: ajmc.com
Rapid growth of medical artificial intelligence technology usage identified from insurance claims analysis, yet major barriers to widespread adoption remain - Vimarsana News

Rapid growth of medical artificial intelligence technology usage identified from insurance claims analysis, yet major barriers to widespread adoption remain

1. The adoption of medical artificial intelligence (AI) technologies has increased exponentially over the past few years, both in terms of total number of claims and the development of new current procedural terminology (CPT) medical AI procedures. 2. Medical AI technology usage was shown to be largely restricted to metropolitan areas and/or those with an

Fixed Venetoclax Dosing May Not Be Feasible for All Patients With CLL - Vimarsana News

Fixed Venetoclax Dosing May Not Be Feasible for All Patients With CLL

The retrospective cohort study evaluated data from 116 patients who received venetoclax as part of their first-line treatment and 145 patients in the relapsed/refractory setting..

Obesity progression may contribute to the economic burden of the disease, studies suggest - Vimarsana News

Obesity progression may contribute to the economic burden of the disease, studies suggest

Obesity is known to approximately double healthcare costs in the US compared to those with a healthy weight.